Cargando…

What is a glioblastoma?

Detalles Bibliográficos
Autores principales:	Lassman, Andrew B, van den Bent, Martin J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237413/ https://www.ncbi.nlm.nih.gov/pubmed/36789896 http://dx.doi.org/10.1093/neuonc/noad044

Ejemplares similares

Recurrent Glioblastoma: What Is the Route?
por: Bosio, Alberto, et al.
Publicado: (2023)

Current usage of tumor treating fields for glioblastoma
por: Lassman, Andrew B, et al.
Publicado: (2020)

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
por: Lassman, Andrew B., et al.
Publicado: (2022)

What to do when there is no standard of care: A brief review of treatment options for glioblastoma in children
por: Scott, Jacob G, et al.
Publicado: (2012)

On high‐risk, low‐grade glioma: What distinguishes high from low?
por: Geurts, Marjolein, et al.
Publicado: (2018)

Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival
por: Ellingson, Benjamin M, et al.
Publicado: (2023)

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2019)

Glioblastomas
por: Finocchiaro, Gaetano, et al.
Publicado: (2021)

The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review
por: Swildens, Kyra X, et al.
Publicado: (2022)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
por: van den Bent, Martin, et al.
Publicado: (2017)

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
por: Lassman, Andrew B, et al.
Publicado: (2019)

Goal-directed therapy: what we know and what we need to know
por: O’Neal, Jason B, et al.
Publicado: (2015)

Macrophages in the Glioblastoma Tumor Microenvironment
por: Coniglio, Salvatore J.
Publicado: (2023)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

Robotic Cardiac Surgery: What the Young Surgeon Should Know
por: den Eynde, Jef Van, et al.
Publicado: (2020)

Modes of immunosuppression in glioblastoma microenvironment
por: Lehtipuro, Suvi, et al.
Publicado: (2019)

Glioblastoma: an organ-confined disease?
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022)

Hypoxia and glioblastoma therapy
por: Yang, Chunzhang, et al.
Publicado: (2015)

Glioblastoma in older adults
por: Holdhoff, Matthias, et al.
Publicado: (2018)

T-cell exhaustion in glioblastoma
por: Woroniecka, Karolina, et al.
Publicado: (2018)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

What puzzle are you in?
por: Yanai, Itai, et al.
Publicado: (2022)

What is the question?
por: Yanai, Itai, et al.
Publicado: (2019)

Basic and Translational Advances in Glioblastoma
por: Piccirillo, Sara G. M., et al.
Publicado: (2018)

MIF: functions in brain and glioblastoma
por: Ohta, Shigeki, et al.
Publicado: (2017)

Novel Treatment Strategies for Glioblastoma
por: Stylli, Stanley S.
Publicado: (2020)

Current Therapeutic Strategies for Glioblastoma
por: Rossignol, Julien, et al.
Publicado: (2019)

Targeted Molecular Therapy in Glioblastoma
por: Festuccia, Claudio, et al.
Publicado: (2020)

The need for geriatric scales in glioblastoma
por: Domenech, Marta, et al.
Publicado: (2021)

Molecular and Cellular Mechanisms of Glioblastoma
por: Castresana, Javier S., et al.
Publicado: (2021)

Editors’ notebook: what is ‘pediatric’?
por: Strouse, Peter J., et al.
Publicado: (2022)

Greater patient access to immuno-oncology therapies—what can policymakers do?
por: de Lorenzo, Francesco, et al.
Publicado: (2015)

Novel Treatment Strategies for Glioblastoma—A Summary
por: Stylli, Stanley S.
Publicado: (2021)

Glioblastoma Biology, Genetics and Possible Therapies
por: Castresana, Javier S., et al.
Publicado: (2023)

Mouse models of radiation-induced glioblastoma
por: Mukherjee, Bipasha, et al.
Publicado: (2015)

On the subventricular zone origin of human glioblastoma
por: Mistry, Akshitkumar M.
Publicado: (2019)

Glioblastoma: State of the Art and Future Perspectives
por: Tabatabai, Ghazaleh, et al.
Publicado: (2019)

Why is immunotherapy for glioblastoma “Lag”-ging
por: Mathios, Dimitrios, et al.
Publicado: (2019)

SERPINA3 in glioblastoma and Alzheimer’s disease
por: Norton, Emily S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4tk7mphpb0seu1lf6lroe61tce